ArticleAesthetic surgery journal. Open forum2026
Hyaluronic Acid vs Poly-L-Lactic Acid for the Treatment of Upper-Eyelid Hollowing: A Prospective Cohort Study.
Article in Aesthetic surgery journal. Open forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Upper-eyelid hollowing can be treated with hyaluronic acid (HA) or poly-L-lactic acid (PLLA), which differ in onset and durability; objective comparative data are limited. Objectives: The aim of this study was to compare 9-month efficacy and safety of HA vs PLLA based on objective image-based metrics and patient-reported outcomes. Methods: This single-center, prospective, nonrandomized cohort study enrolled patients who chose HA (single session) or PLLA (three sessions, 4 weeks apart) after standardized counseling.Three co-primary image-derived metrics-hollow area, mean curvature of the superior sulcus, and arc/chord ratio-were assessed at baseline and at 3, 6, and 9 months after the last treatment (T1-T3). Linear mixed-effects models estimated between-group differences(fixed: group, time, group × time, random: participantwith eye nested), with Holm adjustment for family-wise error.FACE-Q and Upper-Eyelid Hollowing Severity Scale (UEHSS) were secondary endpoints and safety used the full sample. Results: Thirty-six participants (72 eyes) were enrolled, and 66 eyes completed follow-up. In the matched cohort ( Conclusions: HA provides greater early improvement, whereas PLLA yields superior outcomes by 9 months, supporting pathway-based treatment selection. Level of Evidence 3 Therapeutic:
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.